Discovery and Clinical Development of Dutasteride, a Potent Dual 5- Reductase Inhibitor

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|6|5|405-421

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.6, Iss.5, 2006-01, pp. : 405-421

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

By Djavan Bob   Milani Shirin   Fong Yan Kit  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

The Discovery of the Factor Xa Inhibitor Otamixaban: From Lead Identification to Clinical Development

By  

Current Medicinal Chemistry, Vol. 14, Iss. 23, 2007-10 ,pp. : 2471-2481

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

FR226807: a potent and selective phosphodiesterase type 5 inhibitor

By Hosogai N.   Hamada K.   Tomita M.   Nagashima A.   Takahashi T.   Sekizawa T.   Mizutani T.   Urano Y.   Kuroda A.   Sawada K.   Ozaki T.   Seki J.   Goto T.  

European Journal of Pharmacology, Vol. 428, Iss. 2, 2001-10 ,pp. : 295-302

Elsevier

Access to resources Recommend Favorite

KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5

By Hirose R.   Okumura H.   Yoshimatsu A.   Irie J.   Onoda Y.   Nomoto Y.   Takai H.   Ohno T.   Ichimura M.  

European Journal of Pharmacology, Vol. 431, Iss. 1, 2001-11 ,pp. : 17-24

Elsevier

Access to resources Recommend Favorite